nach oben

Erschienen in:

20.02.2020 | Original Article

RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group

verfasst von: Mariana Bastos-Oreiro, Ana Muntañola, Carlos Panizo, Eva Gonzalez-Barca, Sonia González de Villambrosia, Raúl Córdoba, Jose Luís Bello López, Pedro González-Sierra, María José Terol, Antonio Gutierrez, Carlos Grande, María José Ramirez, Laura Iserte, Elena Perez, Belén Navarro, Pilar Gomez, Antonio Salar, Hugo Luzardo, Andrés López, Raquel Del Campo, Daniel García-Belmonte, María Jesús Vida, María Infante, Jose Antonio Queizan-Hernandez, Silvana Novelli, Miriam Moreno, Miriam Penarrubia, Joaquín Gómez, Abel Domingo, Eva Donato, María Cruz Viguria, Francisca López, María José Rodriguez, Emilia Pardal, Victor Noriega, Rafael Andreu, Javier Peñalver, Alejandro Martín, Dolores Caballero, Armando López-Guillermo

Erschienen in: Annals of Hematology | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Lymphomas are a large, heterogeneous group of neoplasms with well-defined characteristics, and this heterogeneity highlights the importance of epidemiological data. Knowledge of local epidemiology is essential to optimise resources, design clinical trials, and identify minority entities. Given there are few published epidemiological data on lymphoma in Spain, the Spanish Lymphoma and Autologous Bone Marrow Transplant Group created the RELINF project. The aim of this project is to determine the frequencies and distribution of lymphoid neoplasms in Spain and to analyse survival. We developed an online platform for the prospective collection of data on newly diagnosed cases of lymphoma in Spain between January 2014 and July 2018; 11,400 patients were registered. Diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL) were the most frequent lymphomas in our series. Marginal B cell lymphoma frequency was higher than that reported in other studies, representing more than 11% of mature B cell lymphomas. Peripheral T cell lymphoma not otherwise specified (PTCL-NOS) was the most common subtype of T cell lymphoma, and NK/T cell lymphomas were more frequent than expected (5.4% of total). Hodgkin’s lymphoma accounted for 12% of lymphoproliferative syndromes. Overall survival was greater than 90% at 2 years for indolent B cell lymphomas, and approximately 60% for DLBCL, somewhat lower than that previously reported. Survival was poor for PTCL-NOS and angioimmunoblastic T cell lymphoma, as expected; however, it was somewhat better than that in other studies for anaplastic large cell anaplastic lymphoma kinase lymphomas. This is the first prospective registry to report the frequencies, distribution, and survival of lymphomas in Spain. The frequencies and survival data we report here are globally consistent with that reported in other Western countries. These updated frequencies and survival statistics are necessary for developing appropriate management strategies for neoplasias in the Spanish population.

Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375–2390CrossRefPubMedPubMedCentral

(1982) National Cancer Institute sponsored study of classifications of non-Hodgkin’s lymphomas: summary and description of a working formulation for clinical usage. The non-Hodgkin’s lymphoma pathologic classification project. Cancer 49(10):2112–2135

Lenz G, Staudt LM (2010) Aggressive lymphomas. N Engl J Med 362(15):1417–1429CrossRefPubMedPubMedCentral

Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma E-J, Greiner TC, Weisenburger DD, Rosenwald A, Ott G, Müller-Hermelink HK, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Grogan TM, Campo E, Jaffe ES, Dave BJ, Sanger W, Bast M, Vose JM, Armitage JO, Connors JM, Smeland EB, Kvaloy S, Holte H, Fisher RI, Miller TP, Montserrat E, Wilson WH, Bahl M, Zhao H, Yang L, Powell J, Simon R, Chan WC, Staudt LM, Lymphoma/Leukemia Molecular Profiling Project (2006) Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med 354(23):2431–2442CrossRefPubMed

Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Rimsza LM, Grogan TM, Miller TP, LeBlanc M, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Connors JM, Lansdorp PM, Ouyang Q, Lister TA, Davies AJ, Norton AJ, Muller-Hermelink HK, Ott G, Campo E, Montserrat E, Wilson WH, Jaffe ES, Simon R, Yang L, Powell J, Zhao H, Goldschmidt N, Chiorazzi M, Staudt LM (2004) Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351(21):2159–2169CrossRefPubMed

Sant M, Allemani C, De Angelis R, Carbone A, de Sanjosè S, Gianni AM et al (2008) Influence of morphology on survival for non-Hodgkin lymphoma in Europe and the United States. Eur J Cancer 44(4):579–587CrossRefPubMed

Sant M, Aareleid T, Berrino F, Bielska Lasota M, Carli PM, Faivre J et al (2003) EUROCARE-3: survival of cancer patients diagnosed 1990-94--results and commentary. Ann Oncol 14(Suppl 5):v61–v118CrossRefPubMed

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386CrossRefPubMed

Wright F, Hapgood G, Loganathan A, Dunn N, Philpot S, Moore J, Mollee P (2018) Relative survival of patients with lymphoma in Queensland according to histological subtype. Med J Aust 209(4):166–172CrossRefPubMed

10.

Tomoka T, Montgomery ND, Powers E, Dhungel BM, Morgan EA, Mulenga M et al (2018) Lymphoma and pathology in sub-Saharan Africa: current approaches and future directions. Clin Lab Med 38(1):91–100CrossRefPubMed

11.

Chihara D, Ito H, Matsuda T, Shibata A, Katsumi A, Nakamura S, Tomotaka S, Morton LM, Weisenburger DD, Matsuo K (2014) Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol 164(4):536–545CrossRefPubMed

12.

Yuan Y, Yang L, Sun T, Li H, Zhu J, Song Y, Wang N (2014) Analysis of lymphoma incidence in Beijing, 1998-2010. Zhonghua Yu Fang Yi Xue Za Zhi 48(8):669–673PubMed

13.

Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS (2006) Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 107(1):265–276CrossRefPubMedPubMedCentral

14.

Marcos-Gragera R, Cervantes-Amat M, Vicente ML, de Sanjosé S, Guallar E, Godoy C, Calvo C, Giraldo P, Sant M, Peris-Bonet R, Carmen Martos M (2010) Population-based incidence of childhood leukaemias and lymphomas in Spain (1993-2002). Eur J Cancer Prev 19(4):247–255CrossRefPubMed

15.

Rodríguez-García JA, Vázquez L, Ramos F, Cuevas B, Martín A, Smucler A et al (2015) Incidence of haematological neoplasms in Castilla y León, Spain. Med Clin (Barc) 144(11):491–500CrossRef

16.

Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O et al (2010) Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 116(19):3724–3734CrossRefPubMed

17.

Smith A, Crouch S, Lax S, Li J, Painter D, Howell D, Patmore R, Jack A, Roman E (2015 Apr 28) Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK’s haematological malignancy research network. Br J Cancer 112(9):1575–1584CrossRefPubMedPubMedCentral

18.

Dandoit M, Mounier M, Guy J, Petrella T, Girard S, Casasnovas R-O, Martin L, Bonnetain F, Maynadié M (2015) The heterogeneity of changes in incidence and survival among lymphoid malignancies in a 30-year French population-based registry. Leuk Lymphoma 56(4):1050–1057CrossRefPubMed

19.

Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR (2016) 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 66:443CrossRefPubMed

20.

Perry AM, Diebold J, Nathwani BN, MacLennan KA, Müller-Hermelink HK, Bast M, Boilesen E, Armitage JO, Weisenburger DD (2016) Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the international non-Hodgkin lymphoma classification project. Haematologica. 101(10):1244–1250CrossRefPubMedPubMedCentral

21.

(1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The non-Hodgkin’s lymphoma classification project. Blood. 89(11):3909–3918

22.

Khalil MO, Morton LM, Devesa SS, Check DP, Curtis RE, Weisenburger DD et al (2014) Incidence of marginal zone lymphoma in the United States, 2001–2009 with a focus on primary anatomic site. Br J Haematol 165(1):67–77CrossRefPubMedPubMedCentral

23.

Abramson JS, Feldman T, Kroll-Desrosiers AR, Muffly LS, Winer E, Flowers CR, Lansigan F, Nabhan C, Nastoupil LJ, Nath R, Goy A, Castillo JJ, Jagadeesh D, Woda B, Rosen ST, Smith SM, Evens AM (2014) Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol 25(11):2211–2217CrossRefPubMedPubMedCentral

24.

Haverkos BM, Pan Z, Gru AA, Freud AG, Rabinovitch R, Xu-Welliver M, Otto B, Barrionuevo C, Baiocchi RA, Rochford R, Porcu P (2016 Dec) Extranodal NK/T-cell lymphoma, nasal type (ENKTL-NT): an update on epidemiology, clinical presentation, and natural history in north American and European cases. Curr Hematol Malig Rep 11(6):514–527CrossRefPubMedPubMedCentral

25.

Barrionuevo C, Zaharia M, Martinez MT, Taxa L, Misad O, Moscol A et al (2007) Extranodal NK/T-cell lymphoma, nasal type: study of clinicopathologic and prognosis factors in a series of 78 cases from Peru. Appl Immunohistochem Mol Morphol 15(1):38–44CrossRefPubMed

26.

Au W, Weisenburger DD, Intragumtornchai T, Nakamura S, Kim W-S, Sng I, Vose J, Armitage JO, Liang R, International Peripheral T-Cell Lymphoma Project (2009) Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the international peripheral T-cell lymphoma project. Blood. 113(17):3931–3937CrossRefPubMed

27.

Treviño A, Alcantara LC, Benito R, Caballero E, Aguilera A, Ramos JM et al (2014) Molecular epidemiology and clinical features of human T cell lymphotropic virus type 1 infection in Spain. AIDS Res Hum Retrovir 30(9):856–862CrossRefPubMedPubMedCentral

28.

de Mendoza C, Caballero E, Aguilera A, Requena S, de Lejarazu RO, Pirón M et al (2017) Human T-lymphotropic virus type 1 infection and disease in Spain. AIDS 31(12):1653–1663CrossRefPubMed

29.

Siegel RL, Miller KD, Jemal A (2018 Jan) Cancer statistics, 2018. CA Cancer J Clin 68(1):7–30CrossRefPubMed

30.

Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin’s disease. International prognostic factors project on advanced Hodgkin’s disease. N Engl J Med 339(21):1506–1514CrossRefPubMed

31.

Klimm B, Goergen H, Fuchs M, von Tresckow B, Böll B, Meissner J et al (2013) Impact of risk factors on outcomes in early-stage Hodgkin’s lymphoma: an analysis of international staging definitions. Ann Oncol 24(12):3070–3076CrossRefPubMed

32.

Böll B, Görgen H (2019) The treatment of older Hodgkin lymphoma patients Br J Haematol 184(1):82–92

33.

Frederiksen JK, Sharma M, Casulo C, Burack WR (2015) Systematic review of the effectiveness of fine-needle aspiration and/or core needle biopsy for subclassifying lymphoma. Arch Pathol Lab Med 139(2):245–251CrossRefPubMed

34.

Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, Feugier P, Bouabdallah R, Catalano JV, Brice P, Caballero D, Haioun C, Pedersen LM, Delmer A, Simpson D, Leppa S, Soubeyran P, Hagenbeek A, Casasnovas O, Intragumtornchai T, Fermé C, da Silva MG, Sebban C, Lister A, Estell JA, Milone G, Sonet A, Mendila M, Coiffier B, Tilly H (2011) Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 377(9759):42–51CrossRefPubMed

35.

Salar A, Domingo-Domenech E, Panizo C, Nicolás C, Bargay J, Muntañola A et al (2017) Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma. Blood 130(15):1772–1774CrossRefPubMed

36.

Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, van den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4):235–242CrossRefPubMed

37.

Horn H, Ziepert M, Becher C, Barth TF, Bernd HW, Feller AC, Klapper W, Hummel M, Stein H, Hansmann ML, Schmelter C, Möller P, Cogliatti S, Pfreundschuh M, Schmitz N, Trümper L, Siebert R, Loeffler M, Rosenwald A, Ott G, German High-Grade Non-Hodgkin Lymphoma Study Group (2013) MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood. 121(12):2253–2263CrossRefPubMed

38.

Shenoy PJ, Malik N, Nooka A, Sinha R, Ward KC, Brawley OW, Lipscomb J, Flowers CR (2011) Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. Cancer. 117(11):2530–2540CrossRefPubMed

39.

Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Brière J, Haioun C, Cazals-Hatem D, Bosly A, Xerri L, Tilly H, Berger F, Bouhabdallah R, Diebold J (1998) Prognostic significance of T-cell phenotype in aggressive non-Hodgkin’s lymphomas. Groupe d’Etudes des Lymphomes de l’Adulte (GELA). Blood. 92(1):76–82PubMed

40.

Federico M, Rudiger T, Bellei M, Nathwani BN, Luminari S, Coiffier B, Harris NL, Jaffe ES, Pileri SA, Savage KJ, Weisenburger DD, Armitage JO, Mounier N, Vose JM (2013) Clinicopathologic characteristics of angioimmunoblastic T cell lymphoma: analysis of the international peripheral T cell lymphoma project. J Clin Oncol 31(2):240–246CrossRefPubMed

41.

Sibon D, Fournier M, Brière J, Lamant L, Haioun C, Coiffier B, Bologna S, Morel P, Gabarre J, Hermine O, Sonet A, Gisselbrecht C, Delsol G, Gaulard P, Tilly H (2012) Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte trials. J Clin Oncol 30(32):3939–3946CrossRefPubMed

42.

Sasse S, Bröckelmann PJ, Goergen H, Plütschow A, Müller H, Kreissl S, Buerkle C, Borchmann S, Fuchs M, Borchmann P, Diehl V, Engert A (2017) Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: updated analyses of the German Hodgkin study group HD7, HD8, HD10, and HD11 trials. J Clin Oncol 35(18):1999–2007CrossRefPubMed

43.

Skoetz N, Will A, Monsef I, Brillant C, Engert A, von Tresckow B (2017) Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma. Cochrane Database Syst Rev 5:CD007941PubMed

44.

Nogová L, Reineke T, Josting A, Müller-Hermelink HK, Eich HT, Behringer K et al (2005) Lymphocyte-predominant and classical Hodgkin’s lymphoma--comparison of outcomes. Eur J Haematol Suppl 66:106–110CrossRef

45.

Tanimura A, Hirai R, Nakamura M, Takeshita M, Hagiwara S, Miwa A (2018) The prognostic impact of dose-attenuated R-chop therapy for elderly patients with diffuse large B-cell lymphoma. Intern Med 57:3521CrossRefPubMedPubMedCentral

46.

Delarue R, Tilly H, Mounier N, Petrella T, Salles G, Thieblemont C, Bologna S, Ghesquières H, Hacini M, Fruchart C, Ysebaert L, Fermé C, Casasnovas O, van Hoof A, Thyss A, Delmer A, Fitoussi O, Molina TJ, Haioun C, Bosly A (2013) Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncol 14(6):525–533CrossRefPubMed

Titel: RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group
verfasst von: Mariana Bastos-Oreiro
Ana Muntañola
Carlos Panizo
Eva Gonzalez-Barca
Sonia González de Villambrosia
Raúl Córdoba
Jose Luís Bello López
Pedro González-Sierra
María José Terol
Antonio Gutierrez
Carlos Grande
María José Ramirez
Laura Iserte
Elena Perez
Belén Navarro
Pilar Gomez
Antonio Salar
Hugo Luzardo
Andrés López
Raquel Del Campo
Daniel García-Belmonte
María Jesús Vida
María Infante
Jose Antonio Queizan-Hernandez
Silvana Novelli
Miriam Moreno
Miriam Penarrubia
Joaquín Gómez
Abel Domingo
Eva Donato
María Cruz Viguria
Francisca López
María José Rodriguez
Emilia Pardal
Victor Noriega
Rafael Andreu
Javier Peñalver
Alejandro Martín
Dolores Caballero
Armando López-Guillermo
Publikationsdatum: 20.02.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Annals of Hematology / Ausgabe 4/2020
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-020-03918-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2020

Prevalence of pulmonary hypertension in myelofibrosis

Burden of illness among patients with severe aplastic anemia who have had insufficient response to immunosuppressive therapy: a multicenter retrospective chart review study

Clone wars: co-occurrence of IDH2 R140Q and R172K in myelodysplastic syndromes

Chemogenomics analysis of drug targets for the treatment of acute promyelocytic leukemia

Antiemetic prophylaxis in patients undergoing hematopoietic stem cell transplantation: a multicenter survey of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) transplant programs